|drug2999||Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells Wiki||1.00|
|drug321||Anticoagulant Therapy Wiki||1.00|
There is one clinical trial.
Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.
Description: Improvement of pulmonary function. Arterial oxygen tension PaO2 (in mmHg)/fractional inspired oxygen FiO2 (expressed as a fraction, not a percentage), most conveniently the P/F ratio. The normal P/F ratio is ~ 400-500 mmHg (~55-65 kPa). P/F ratio <300mmHg - sign of Acute Respiratory Distress Syndrome (ARDS)Measure: Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio. Time: up to 28 days
Description: Length of Hospital StayMeasure: Changes in length of hospital stay Time: up to 28 days
Description: Marker for efficacy of treatmentMeasure: Changes in mortality rate Time: up to 28 days
Description: Infection biomarker. Serum CRP levels can be used for early diagnosis of pneumonia, patients with severe pneumonia had high CRP levels.Measure: Changes of С-reactive protein (CRP, mg/L) Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Description: CT assessment of pulmonary lesions and lung tissue changesMeasure: Evaluation of Pneumonia Improvement Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Description: Indirect response to lung functionMeasure: Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.) Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Description: Degree of infectionMeasure: Peripheral blood count recovery time Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports